Evidence map›Paper›PMID 35543159›Full record

ArticleMolecular medicine reports2022

Mesenchymal stem cell‑derived exosomes loaded with 5‑Fu against cholangiocarcinoma

Mingzheng Chen, Yangyang Li, Ningfu Ma, Jinfeng Zang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. [LncRNA SOX2OT enhances 5-fluorouracil resistance of cholangiocarcinoma cells by promoting autophagyNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mingzheng ChenDepartment of Medicine, Graduate School, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Yangyang LiDepartment of Medicine, Graduate School, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Ningfu MaDepartment of Medicine, Graduate School, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Jinfeng ZangDepartment of Hepatobiliary Surgery, Taizhou People's Hospital, The Fifth Affiliated Hospital of The Medical School of Nantong University, Taizhou, Jiangsu 225300, P.R. China.
Dalian Medical University · CNTaizhou People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiocarcinoma (CCA) is an intractable malignant tumour with a high degree of malignancy that is asymptomatic in the early stages. Exosomes have been shown in numerous studies in recent years to be effective delivery vehicles for chemotherapy drugs to suppress tumour proliferation and growth

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaExosomesMesenchymal Stem CellsBile Ducts, IntrahepaticFluorouracilHumansFluorouracil5‑fluorouracilcholangiocarcinomadrug deliveryexosome

Identifiers

PMID35543159
PMCPMC9133964
OpenAlexW4229372357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.